Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit
Source: SeekingAlpha
2026-03-04 06:57:42 ET
More on Sanofi, Sino Biopharmaceutical Limited
- Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
- Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
- Sanofi 2025 Q4 - Results - Earnings Call Presentation
- Sanofi replaces CEO Paul Hudson, names Belén Garijo as successor
- Sanofi anticipates profitable growth to continue over at least five years
Read the full article on Seeking Alpha
For further details see:
Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit
Banco Santander S.A. Sponsored ADR
NASDAQ: SAN
SAN Trading
-1.85% G/L:
$10.86 Last:
7,497,165 Volume:
$11.05 Open:
SAN Latest News
February 03, 2026 01:38:00 pm
Webster Financial Corporation Enters Into Merger Agreement With Banco Santander, S.A. for $12.3 Billion
SAN Stock Data
$212,542,521,684
14,572,031,202
2.7%
312
N/A
Banking
Finance
ES
Boadilla del Monte
